Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$846M |
| 2 |
JD.com
JD
|
+$782M |
| 3 |
Dollar General
DG
|
+$647M |
| 4 |
Monster Beverage
MNST
|
+$324M |
| 5 |
NXP Semiconductors
NXPI
|
+$240M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Union Pacific
UNP
|
+$668M |
| 2 |
Mondelez International
MDLZ
|
+$528M |
| 3 |
Alibaba
BABA
|
+$457M |
| 4 |
TWTR
Twitter, Inc.
TWTR
|
+$409M |
| 5 |
CELG
Celgene Corp
CELG
|
+$403M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.97% |
| 2 | Consumer Discretionary | 16.01% |
| 3 | Technology | 12.95% |
| 4 | Communication Services | 12.43% |
| 5 | Financials | 9.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
676
Akamai
AKAM
$15.6B
| $1.01M | ﹤0.01% |
+14,531
| New | +$1.08M |
|
677
ITT
ITT
$17.1B
| $1.01M | ﹤0.01% |
+24,067
| New | +$1M |
|
|
SEE
678
DELISTED
Sealed Air
SEE
| $988K | ﹤0.01% |
+19,232
| New | +$924K |
|
679
Evolent Health
EVH
$371M
| $972K | ﹤0.01% |
+49,826
| New | +$929K |
|
680
Expedia Group
EXPE
$36.5B
| $967K | ﹤0.01% |
+8,842
| New | +$915K |
|
|
BRKL
681
DELISTED
Brookline Bancorp
BRKL
| $939K | ﹤0.01% |
83,199
+13,219
| +19% | +$144K |
|
|
IPHI
682
DELISTED
INPHI CORPORATION
IPHI
| $924K | ﹤0.01% |
40,424
-35,966
| -47% | -$799K |
|
|
FPO
683
DELISTED
First Potomac Realty Trust
FPO
| $898K | ﹤0.01% |
87,229
-1,879,342
| -96% | -$20.3M |
|
684
Insperity
NSP
$2.03B
| $870K | ﹤0.01% |
34,174
+5,116
| +18% | +$134K |
|
685
Charles River Laboratories
CRL
$11.3B
| $856K | ﹤0.01% |
+12,169
| New | +$901K |
|
|
BDBD
686
DELISTED
BOULDER BRANDS INC
BDBD
| $855K | ﹤0.01% |
123,269
-7,159
| -5% | -$64.6K |
|
|
RATE
687
DELISTED
Bankrate Inc
RATE
| $839K | ﹤0.01% |
79,999
-121,443
| -60% | -$1.47M |
|
688
Macy's
M
$6.51B
| $833K | ﹤0.01% |
12,342
-46,651
| -79% | -$3.15M |
|
689
Ashland
ASH
$3.34B
| $817K | ﹤0.01% |
13,705
-2,567
| -16% | -$160K |
|
|
NAK
690
Northern Dynasty Minerals
NAK
$773M
| $815K | ﹤0.01% |
2,397,185
-8,372
| -0.3% | -$3.19K |
|
|
KRA
691
DELISTED
Kraton Corporation
KRA
| $807K | ﹤0.01% |
33,805
-2,354
| -7% | -$53K |
|
692
Lockheed Martin
LMT
$131B
| $768K | ﹤0.01% |
+4,132
| New | +$796K |
|
|
HSII
693
DELISTED
Heidrick & Struggles
HSII
| $764K | ﹤0.01% |
29,305
+1,008
| +4% | +$25.2K |
|
694
Outfront Media
OUT
$5.75B
| $737K | ﹤0.01% |
+29,673
| New | +$817K |
|
695
Crown Holdings
CCK
$13B
| $687K | ﹤0.01% |
12,991
-2,871
| -18% | -$158K |
|
696
Dorman Products
DORM
$4.22B
| $679K | ﹤0.01% |
14,238
-28,777
| -67% | -$1.4M |
|
|
SHLM
697
DELISTED
Schulman (A.) Inc
SHLM
| $632K | ﹤0.01% |
14,462
+3,845
| +36% | +$171K |
|
698
Crane NXT
CXT
$2.99B
| $629K | ﹤0.01% |
30,854
-73,636
| -70% | -$1.57M |
|
699
Omnicell
OMCL
$1.88B
| $621K | ﹤0.01% |
16,460
-770
| -4% | -$28.1K |
|
700
Vitamin Cottage Natural Grocers
NGVC
$760M
| $595K | ﹤0.01% |
24,177
-1,134
| -4% | -$29.1K |
|
Similar funds
Jennison Associates's Q2 2015 Portfolio in Review
As of Q2 2015, Jennison Associates held 801 positions worth $109B, down 0.05% from $109B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Jennison Associates's Q2 2015 filing shows 92 new, 315 increased, 305 reduced and 72 closed positions. Its largest new stake was Regeneron Pharmaceuticals: 1,732,726 shares worth $884M. The largest sale was Union Pacific, an estimated $668M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Technology.
- Jennison Associates's largest Q2 2015 buy was Regeneron Pharmaceuticals: 1,732,726 shares worth $884M.
- Jennison Associates added most to JD.com in Q2 2015, an estimated $782M increase.
- Jennison Associates's biggest Q2 2015 reduction was Union Pacific, cutting an estimated $668M.
- Jennison Associates fully exited Perrigo in Q2 2015, selling an estimated $204M.
- Jennison Associates's ten largest holdings make up 21% of its $109B portfolio in Q2 2015.
- Jennison Associates opened 92 new positions and closed 72 in Q2 2015.
- Jennison Associates's portfolio value fell 0.05% quarter-over-quarter to $109B.
Based on Jennison Associates's 13F filing for Q2 2015, filed 3 Aug 2015.